BC
ROIV icon

Brookfield Corp’s Roivant Sciences ROIV Stock Holding History

Brookfield Corp’s Portfolio ROIV Stock Details ROIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-149,200
Closed -$607K – 749
2022
Q2 		$607K Hold
149,200
– – ﹤0.01% 534
2022
Q1 		$737K Buy
+149,200
New +$984K ﹤0.01% 529

Other funds holding ROIV

QF
QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HH
HSG Holding Na, Hong Kong $1.2B AUM 23.01% 1-Year Est. Return
ACG
Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Brookfield Corp's ROIV Position: Q3 2022 in Review

Brookfield Corp sold out of Roivant Sciences (ROIV) in Q3 2022, closing a stake of 149,200 shares — an estimated $607K sold.

Brookfield Corp first reported a position in ROIV in Q1 2022 and held it in 2 quarters. The position peaked at $737K in Q1 2022. 78 funds tracked by Wall St. Rank hold ROIV as of Q3 2022.

  • Brookfield Corp reported no remaining Roivant Sciences position as of Q3 2022 after selling out during the quarter.
  • Brookfield Corp sold 149,200 Roivant Sciences shares in Q3 2022, an estimated $607K.
  • Brookfield Corp first reported a position in Roivant Sciences in Q1 2022 and held it in 2 quarters.
  • Brookfield Corp's Roivant Sciences position peaked at $737K in Q1 2022.
  • 78 funds tracked by Wall St. Rank held Roivant Sciences as of Q3 2022.

Based on Brookfield Corp's 13F filing for Q3 2022, filed 14 Nov 2022.